379 Can Prolyl Endoprotease Enzyme Treatment Mitigate the Toxic Effect of Gluten in Coeliac Patients?

Tack, Greetje J.; Water, Jolanda M. van de; Kooy-Winkelaar, Engelina M C; Bergen, Jeroen van; Meijer, Gerrit A.; Blomberg, Boudewina M. von; Schreurs, Marco W. J.; Bruins, Maaike J.; Edens, Luppo; Mulder, Chris J.; Koning, Frits

doi:10.1016/s0016-5085(10)60247-8

Cited by 11 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a pilot clinical trial (NCT00810654), AN PEP (DSM Food Specialties) or placebo-containing jam was administered to CD patients with a breakfast comprising 7 g of gluten twice in 2 weeks. No significant histopathological or serological differences between AN PEP and placebo were observed as too few patients in the control group showed a disease flare (43). AN PEP is particularly active to degrade gluten in the stomach and is being considered as potential food supplement.…”

Section: Oral Enzyme Supplementationmentioning

confidence: 98%

Celiac Disease: A Challenging Disease for Pharmaceutical Scientists

2012

View full text Add to dashboard Cite

Celiac disease (CD) is an immune-mediated enteropathy triggered by the ingestion of gluten-containing grains that affects~1% of the white ethnic population. In the last decades, a rise in prevalence of CD has been observed that cannot be fully explained by improved diagnostics. Genetic predisposition greatly influences the susceptibility of individuals towards CD, though environmental factors also play a role. With no pharmacological treatments available, the only option to keep CD in remission is a strict and permanent exclusion of dietary gluten. Such a gluten-free diet is difficult to maintain because of gluten's omnipresence in food (e.g., additive in processed food). The development of adjuvant therapies which would permit the intake of small amounts of gluten would be desirable to improve the quality of life of patients on a glutenfree diet. Such therapies include gluten-degrading enzymes, polymeric binders, desensitizing vaccines, anti-inflammatory drugs, transglutaminase 2 inhibitors, and HLA-DQ2 blockers. However, many of these approaches pose pharmaceutical challenges with respect to drug formulation and stability, or application route and dosing interval. This perspective article discusses how pharmaceutical scientists may deal with these challenges and contribute to the implementation of novel therapeutic options for patients with CD.

show abstract

Section: Oral Enzyme Supplementationmentioning

confidence: 98%

Celiac Disease: A Challenging Disease for Pharmaceutical Scientists

2012

View full text Add to dashboard Cite

show abstract

“…An alternative to the gluten-free diet is the elimination of coeliac toxic and immunogenic peptide fragments at the stage of food production or by supporting the digestion in the human gastrointestinal tract [20][21][22][23]. Studies on the degradation of gluten by oral enzyme therapy are focused on the use of bacterial prolyl endopeptidases from Flavobacterium meningosepticum, Myxococcus xanthus and Sphingomonas capsulata [24], prolyl endopeptidase from Aspergillus niger [25] and cysteine endopeptidase from germinating barley grains (EP-B2) [16].…”

Section: Introductionmentioning

confidence: 99%

Immunoreactivity of wheat proteins modified by hydrolysis and polymerisation

Brzozowski

2015

Eur Food Res Technol

View full text Add to dashboard Cite

show abstract

“…Although encapsulation of PEPs was proposed in order to protect them from gastric secretions, recent studies have shown that only high doses of PEPs are capable of eliminating immunogenic peptides in a daily gluten load 35,36 . AN-PEP is an enzyme derived from Aspergillus niger that is being developed by an alimentary company (DSM) 37 . In vitro studies have shown that AN-PEP is active at acidic pH, resists digestion by pepsin and degrades all tested gluten peptides with a half-life ranging between 2 and 6 minutes 34,38 .…”

Section: Flavobacterium Meningosepticum Sphingomonas Capsulata and Mmentioning

confidence: 99%